ReproNovo

What ReproNovo does

ReproNovo is a clinical-stage biopharmaceutical company founded in 2021 and headquartered in Lausanne, Switzerland, with primary R&D and clinical operations in Copenhagen, Denmark and Barcelona, Spain. It is developing two Phase 2 drug candidates for reproductive medicine and women's health: RPN-001 (leflutrozole), an orally administered aromatase inhibitor intended for male infertility associated with low serum testosterone, and RPN-002 (nolasiban), an orally administered oxytocin receptor antagonist being developed for both adenomyosis symptom management and improving embryo implantation success rates in assisted reproductive technology (ART). Both assets were secured through in-licensing — an exclusive global license for leflutrozole from Mereo BioPharma and acquisition of exclusive rights to nolasiban from ObsEva — giving the company sole control over its entire pipeline.

The company has no commercial revenue or approved products; its go-to-market model is a traditional pharmaceutical commercialization framework, with plans to either build direct commercial capabilities or pursue strategic out-licensing partnerships once assets receive regulatory approval. Pricing has not been disclosed and distribution is expected to rely on established pharmaceutical wholesalers and specialty pharmacy channels upon launch. End markets are fragmented across three patient populations — men with hypogonadism-related infertility, women with adenomyosis, and couples undergoing IVF/ART — all of which have significant unmet need and limited or no approved oral/targeted pharmacotherapies.

ReproNovo is backed by a syndicate of specialized European healthcare investors (Jeito Capital, AXA IM Alts, M Ventures, Ysios Capital, ALSA Ventures) that closed a $65 million Series A in May 2025, with board representation from each lead investor and a chairman (Mark Altmeyer) installed in March 2026. The leadership team is heavily sourced from Ferring Pharmaceuticals and Novo Nordisk, providing deep reproductive medicine drug development experience, and the company has initiated a U.S. Phase 2 trial of RPN-001 (first patient July 2025) and secured China NMPA clearance for a Phase 1 program in the same asset.

Name

ReproNovo

Legal name

ReproNovo ApS

Website

https://repronovo.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

ReproNovo is a clinical-stage biopharmaceutical company developing two Phase 2 drug candidates, RPN-001 (leflutrozole) for male infertility and RPN-002 (nolasiban) for adenomyosis and ART embryo implantation, targeting reproductive medicine and women's health conditions with high unmet need.

Ownership category

akta.pro rank

Product category

Reproductive Medicine and Women's Health Biopharmaceuticals

NAICS

Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)

akta.pro secondary industries

Rare Endocrine & Growth Disorder Therapies (HLAIAIAJ), Reproductive Endocrinology & Infertility (IVF/Fertility) (HLAKAJAC)

Keywords

• Reproductive medicine therapeutics
• Women's health pharmaceuticals
• Male infertility treatment
• Adenomyosis drug development
• Assisted reproductive technology

Headquarters

HQ city

Lausanne

HQ country

Switzerland

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Pharmaceutical Product Sales: ReproNovo is a clinical-stage biopharmaceutical company without current revenue. The company plans to commercialize its pipeline compounds RPN-001 and RPN-002 upon successful regulatory approval. Revenue will be generated through prescription pharmaceutical product sales for male infertility, adenomyosis management, and ART improvement treatments.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

ReproNovo develops two Phase 2 clinical-stage small-molecule drug candidates for reproductive medicine and women's health: RPN-001 (leflutrozole), an oral aromatase inhibitor for male infertility in men with low serum testosterone, and RPN-002 (nolasiban), an oral oxytocin receptor antagonist being advanced for improving embryo implantation in ART/IVF and for managing adenomyosis. The assets are being progressed through clinical development toward regulatory approval and commercialization, leveraging exclusive global licenses from Mereo BioPharma and ObsEva.

Product overview

ReproNovo is a clinical-stage biopharmaceutical company developing two Phase 2 drug candidates for reproductive medicine and women's health. RPN-001 (leflutrozole) is an orally administered aromatase inhibitor for male infertility, while RPN-002 (nolasiban) is an oxytocin receptor antagonist targeting both embryo implantation in ART treatments and adenomyosis management. Both assets are in Phase 2 clinical development.

Differentiator

Problem solved

Functional benefit

Products and services

• RPN-001 (leflutrozole) Orally administered aromatase inhibitor in Phase 2 development for the treatment of male infertility in men with low serum testosterone and impaired semen quality. The small molecule inhibits aromatase, suppressing testosterone conversion to estradiol, normalizing testosterone levels and rebalancing the testosterone-to-estradiol ratio, while stimulating FSH and LH production to improve testicular function and spermatogenesis. No FDA-approved oral therapy currently exists for this indication.
• RPN-002 (nolasiban) Orally administered oxytocin receptor antagonist in Phase 2 development for two indications: (1) improving embryo implantation success rates in women undergoing assisted reproductive technology (ART/IVF), and (2) managing adenomyosis symptoms. Works by establishing uterine quiescence, reducing abnormal uterine contractility, increasing endometrial blood flow, and may reduce local tissue inflammation and relieve menstrual pain. Targets indications with no approved targeted drug therapies.

Quantifiable outcome

• Prevalence of low testosterone in men under 40 has increased five-fold to 20-23%
• +3 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Two partnerships are on record, tiered core.

• Mereo BioPharmacoreTechnology or IntegrationLicensor for leflutrozole compound. ReproNovo has an exclusive global license agreement with Mereo BioPharma for the development and commercialization of leflutrozole (RPN-001) for male infertility treatment.
• ObsEva (formerly)coreTechnology or IntegrationSource of nolasiban assets. ReproNovo acquired the exclusive rights, including all intellectual property and associated assets, related to nolasiban (now RPN-002) from ObsEva for adenomyosis management and improving embryo implantation success rates in ART treatments.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Ferring Pharmaceuticals: Private global leader in reproductive medicine and maternal health, headquartered in Switzerland. Directly comparable because ReproNovo's leadership and most of its development team came from Ferring, and Ferring operates the dominant commercial franchise in the same indications ReproNovo is pursuing (infertility, ART).
• Myovant Sciences: Women's health and endocrine clinical-stage biopharma (acquired by Sumitomo Pharma). Directly comparable as a women's-health focused biopharma advancing novel therapies for uterine conditions and reproductive endocrinology through late-stage development and commercial launch.
• TherapeuticsMD: US women's-health pharmaceutical company commercializing novel therapies in reproductive health, menopause, and prenatal care. Comparable as a similarly focused women's-health pharma developing and commercializing branded, indication-specific therapies in reproductive medicine.

Emerging players

• Mereo BioPharma: UK-listed clinical-stage biopharma focused on rare disease. Directly comparable as the licensor of RPN-001 (leflutrozole) to ReproNovo; both are small-cap, clinical-stage companies developing late-stage assets acquired or in-licensed from larger players.
• ObsEva: Swiss clinical-stage biopharma focused on women's health and reproductive medicine. Directly comparable as the prior developer/owner of nolasiban (now RPN-002 at ReproNovo), and similarly small-cap, Phase 2-stage, and concentrated in reproductive indications.
• Crinetics Pharmaceuticals: US clinical-stage biopharma developing oral small-molecule therapies for endocrine conditions including hypogonadism and other hormone-related disorders. Comparable as a clinical-stage small-molecule endocrine company targeting adjacent endocrinology indications (including testosterone regulation) with similar stage and modality profile.

Broad incumbents

• Gedeon Richter: Hungarian-listed specialty pharma with a major women's-health franchise (contraception, fertility, gynaecology). Comparable as a broader incumbent selling branded reproductive-medicine therapies globally, with overlapping therapeutic categories to ReproNovo's targets.
• Organon & Co. US-listed women's-health pure-play spun out of Merck, with established franchises in fertility, contraception, and reproductive medicine. Comparable as a broad incumbent with overlapping commercial footprint in reproductive medicine and proven scale in women's-health commercialization.
• Merck KGaA: German science-and-technology group with a global fertility-treatment franchise (Gonal-f, Cetrotide). Comparable as a broad incumbent with a large, established commercial reproductive-medicine portfolio; also directly relevant as the corporate parent of ReproNovo investor M Ventures.
• Bayer (Pharmaceuticals): Global pharma with a women's-health franchise spanning contraception, menopause, and reproductive medicine. Comparable as a broad incumbent operating in overlapping reproductive-medicine categories with substantially greater scale and commercial reach than ReproNovo.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/repronovo

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Funding overview

Funding rounds1 record

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ReproNovo